Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Explore this paper's citation graph
Summary
Vaccination with Ch adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 can result in the rare development of immuneThrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thromBocy topenia.
- Type
- article
- Published
- 2021-04-09
- Cited by
- 1,773
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W3140226555
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:233192850
Keywords
Medicine, Platelet factor 4, Thrombosis, Heparin-induced thrombocytopenia, Deep vein
References
- Decision Making And Problem Solving
- First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA
- Delayed-Onset Heparin-Induced Thrombocytopenia
- Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver
- Fatal heparin‐induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT?
- A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia.
- Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.
- Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia
- Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder.
- Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.
- Pentosan polysulfate‐induced thrombocytopenia and thrombosis
- Distinguishing between anti–platelet factor 4/heparin antibodies that can and cannot cause heparin‐induced thrombocytopenia
- Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.
- A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.
- IVIg for Treatment of Severe Refractory Heparin‐Induced Thrombocytopenia
- Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity
- Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.
- Autoimmune heparin‐induced thrombocytopenia
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
- An international external quality assessment for laboratory diagnosis of heparin‐induced thrombocytopenia
Cited by
- Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data
- COVID-19 vaccines and thrombosis
- Subsequent Vaccination against SARS-CoV-2 after Vaccine-Induced Immune Thrombotic Thrombocytopenia
- Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
- Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding
- Overview of COVID-19
- Lessons from the United Kingdom’s COVID‐19 vaccination strategy
- Safety of COVID-19 vaccines administered in the EU: Should we be concerned?
- Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase
- Covid-19: Vaccine woes highlight vital role of traditional public health
- Review of: "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant"
- Towards Understanding ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
- Continuing COVID-19 Vaccination of Front-Line Workers in British Columbia with the AstraZeneca Vaccine: Benefits in the Face of Increased Risk for Prothrombotic Thrombocytopenia
- SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
- Syndrome of cerebral venous sinus thrombosis and thrombocytopenia after vaccination for COVID-19
- Incidence of cerebral venous sinus thrombosis in adults in Germany – a retrospective study using health claims data
- Recommendations for the clinical and laboratory diagnosis of VITT against COVID‐19: Communication from the ISTH SSC Subcommittee on Platelet Immunology
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
- Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us – and what they don't
- Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors
Related papers
- A Platelet Factor 4‐Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin‐Induced Thrombocytopenia Antibodies
- The Appropriateness of Testing Platelet Factor 4/Heparin Antibody in Patients Suspected of Heparin-induced Thrombocytopenia
- Heparin-induced thrombocytopenia.
- Heparin-induced thrombocytopenia: impact of bovine versus porcine heparin in HIT pathogenesis.
- Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4
- [Anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia--review].
- Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.
- Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4–heparin antibodies to platelets and the resultant platelet activation
- HEPARIN‐INDUCED THROMBOCYTOPENIA IN DIALYSIS: The Pathophysiology of Immune‐mediated Heparin‐induced Thrombocytopenia
- A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis (HIT)